The sale of the Life Sciences & Healthcare segment for $600 million will sharpen focus on core markets, improve financial metrics, and reduce leverage. Management expects enhanced innovation, margin expansion, and sustained free cash flow after closing.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.